nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxorubicin—Epirubicin—uterine cancer	0.188	1	CrCtD
Doxorubicin—Anthracyclines—Epirubicin—uterine cancer	0.11	0.438	CiPCiCtD
Doxorubicin—Topoisomerase Inhibitors—Etoposide—uterine cancer	0.0836	0.333	CiPCiCtD
Doxorubicin—AKR1C3—uterine cancer	0.083	1	CbGaD
Doxorubicin—Topoisomerase Inhibitors—Epirubicin—uterine cancer	0.0575	0.229	CiPCiCtD
Doxorubicin—ovarian cancer—uterine cancer	0.0499	0.357	CtDrD
Doxorubicin—muscle cancer—uterine cancer	0.0499	0.357	CtDrD
Doxorubicin—Valrubicin—Epirubicin—uterine cancer	0.0398	0.333	CrCrCtD
Doxorubicin—Idarubicin—Epirubicin—uterine cancer	0.0398	0.333	CrCrCtD
Doxorubicin—Daunorubicin—Epirubicin—uterine cancer	0.0398	0.333	CrCrCtD
Doxorubicin—sarcoma—uterine cancer	0.0398	0.285	CtDrD
Doxorubicin—AKR1C3—Medroxyprogesterone Acetate—uterine cancer	0.0226	0.162	CbGbCtD
Doxorubicin—YWHAG—Epirubicin—uterine cancer	0.0169	0.121	CbGbCtD
Doxorubicin—AURKA—Epirubicin—uterine cancer	0.0169	0.121	CbGbCtD
Doxorubicin—DHCR7—Epirubicin—uterine cancer	0.0169	0.121	CbGbCtD
Doxorubicin—ABCC6—Dactinomycin—uterine cancer	0.00892	0.0639	CbGbCtD
Doxorubicin—NQO1—Carboplatin—uterine cancer	0.00717	0.0513	CbGbCtD
Doxorubicin—ABCC6—Etoposide—uterine cancer	0.00503	0.0361	CbGbCtD
Doxorubicin—ABCB11—Progesterone—uterine cancer	0.00467	0.0335	CbGbCtD
Doxorubicin—CYP1B1—Progesterone—uterine cancer	0.00467	0.0335	CbGbCtD
Doxorubicin—ABCC10—Etoposide—uterine cancer	0.00385	0.0275	CbGbCtD
Doxorubicin—XDH—Carboplatin—uterine cancer	0.00375	0.0268	CbGbCtD
Doxorubicin—TOP2A—Epirubicin—uterine cancer	0.00344	0.0246	CbGbCtD
Doxorubicin—ABCC1—Progesterone—uterine cancer	0.00332	0.0238	CbGbCtD
Doxorubicin—TOP2A—Etoposide—uterine cancer	0.00268	0.0192	CbGbCtD
Doxorubicin—ABCC1—Dactinomycin—uterine cancer	0.00263	0.0188	CbGbCtD
Doxorubicin—ABCC3—Etoposide—uterine cancer	0.00242	0.0173	CbGbCtD
Doxorubicin—ABCC1—Epirubicin—uterine cancer	0.00191	0.0136	CbGbCtD
Doxorubicin—ABCG2—Dactinomycin—uterine cancer	0.00176	0.0126	CbGbCtD
Doxorubicin—ABCC1—Etoposide—uterine cancer	0.00148	0.0106	CbGbCtD
Doxorubicin—ABCC2—Carboplatin—uterine cancer	0.00131	0.00938	CbGbCtD
Doxorubicin—ABCG2—Carboplatin—uterine cancer	0.00118	0.00848	CbGbCtD
Doxorubicin—ABCC2—Etoposide—uterine cancer	0.0011	0.00787	CbGbCtD
Doxorubicin—ABCG2—Etoposide—uterine cancer	0.000994	0.00712	CbGbCtD
Doxorubicin—ABCB1—Progesterone—uterine cancer	0.000801	0.00573	CbGbCtD
Doxorubicin—CYP2D6—Progesterone—uterine cancer	0.000754	0.0054	CbGbCtD
Doxorubicin—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.000724	0.00519	CbGbCtD
Doxorubicin—ABCB1—Dactinomycin—uterine cancer	0.000635	0.00455	CbGbCtD
Doxorubicin—CYP3A4—Progesterone—uterine cancer	0.00048	0.00344	CbGbCtD
Doxorubicin—ABCB1—Etoposide—uterine cancer	0.000358	0.00257	CbGbCtD
Doxorubicin—NOS1—artery—uterine cancer	0.000321	0.017	CbGeAlD
Doxorubicin—CBR3—myometrium—uterine cancer	0.000265	0.014	CbGeAlD
Doxorubicin—SLC22A16—renal system—uterine cancer	0.000258	0.0136	CbGeAlD
Doxorubicin—NOS3—artery—uterine cancer	0.000244	0.0129	CbGeAlD
Doxorubicin—CYP3A4—Etoposide—uterine cancer	0.000215	0.00154	CbGbCtD
Doxorubicin—SLC22A16—female reproductive system—uterine cancer	0.000207	0.0109	CbGeAlD
Doxorubicin—CBR3—uterine cervix—uterine cancer	0.000206	0.0109	CbGeAlD
Doxorubicin—AKR1A1—myometrium—uterine cancer	0.000205	0.0108	CbGeAlD
Doxorubicin—ABCB8—decidua—uterine cancer	0.000204	0.0108	CbGeAlD
Doxorubicin—ABCB8—renal system—uterine cancer	0.000201	0.0106	CbGeAlD
Doxorubicin—CBR3—decidua—uterine cancer	0.000197	0.0104	CbGeAlD
Doxorubicin—CBR3—endometrium—uterine cancer	0.000187	0.00986	CbGeAlD
Doxorubicin—CBR3—mammalian vulva—uterine cancer	0.000181	0.00954	CbGeAlD
Doxorubicin—AURKA—myometrium—uterine cancer	0.000173	0.00914	CbGeAlD
Doxorubicin—ABCB8—female reproductive system—uterine cancer	0.000161	0.00849	CbGeAlD
Doxorubicin—AKR1A1—uterine cervix—uterine cancer	0.000159	0.00842	CbGeAlD
Doxorubicin—AKR1A1—smooth muscle tissue—uterine cancer	0.000155	0.00818	CbGeAlD
Doxorubicin—CBR3—female reproductive system—uterine cancer	0.000155	0.00817	CbGeAlD
Doxorubicin—NDUFS2—myometrium—uterine cancer	0.000154	0.00815	CbGeAlD
Doxorubicin—NDUFS3—myometrium—uterine cancer	0.000152	0.00805	CbGeAlD
Doxorubicin—AKR1A1—decidua—uterine cancer	0.000152	0.00802	CbGeAlD
Doxorubicin—AKR1A1—renal system—uterine cancer	0.000149	0.00788	CbGeAlD
Doxorubicin—ABCB8—female gonad—uterine cancer	0.000146	0.00772	CbGeAlD
Doxorubicin—NDUFS7—uterine cervix—uterine cancer	0.000145	0.00765	CbGeAlD
Doxorubicin—AKR1A1—endometrium—uterine cancer	0.000144	0.00762	CbGeAlD
Doxorubicin—CBR3—female gonad—uterine cancer	0.000141	0.00743	CbGeAlD
Doxorubicin—CBR3—vagina—uterine cancer	0.00014	0.00739	CbGeAlD
Doxorubicin—AKR1A1—mammalian vulva—uterine cancer	0.000139	0.00737	CbGeAlD
Doxorubicin—NDUFS7—renal system—uterine cancer	0.000135	0.00716	CbGeAlD
Doxorubicin—AURKA—uterine cervix—uterine cancer	0.000135	0.00711	CbGeAlD
Doxorubicin—AKR1A1—uterus—uterine cancer	0.000133	0.00702	CbGeAlD
Doxorubicin—YWHAG—myometrium—uterine cancer	0.000133	0.00702	CbGeAlD
Doxorubicin—AURKA—renal system—uterine cancer	0.000126	0.00666	CbGeAlD
Doxorubicin—NOS1—epithelium—uterine cancer	0.000122	0.00644	CbGeAlD
Doxorubicin—AURKA—endometrium—uterine cancer	0.000122	0.00643	CbGeAlD
Doxorubicin—NDUFS2—uterine cervix—uterine cancer	0.00012	0.00634	CbGeAlD
Doxorubicin—RALBP1—myometrium—uterine cancer	0.00012	0.00634	CbGeAlD
Doxorubicin—AKR1A1—female reproductive system—uterine cancer	0.000119	0.00631	CbGeAlD
Doxorubicin—NDUFS3—uterine cervix—uterine cancer	0.000119	0.00626	CbGeAlD
Doxorubicin—AURKA—mammalian vulva—uterine cancer	0.000118	0.00622	CbGeAlD
Doxorubicin—NOS1—smooth muscle tissue—uterine cancer	0.000117	0.0062	CbGeAlD
Doxorubicin—NDUFS2—smooth muscle tissue—uterine cancer	0.000117	0.00616	CbGeAlD
Doxorubicin—NDUFS3—smooth muscle tissue—uterine cancer	0.000115	0.00609	CbGeAlD
Doxorubicin—NDUFS2—decidua—uterine cancer	0.000114	0.00604	CbGeAlD
Doxorubicin—NOS1—renal system—uterine cancer	0.000113	0.00597	CbGeAlD
Doxorubicin—NDUFS3—decidua—uterine cancer	0.000113	0.00597	CbGeAlD
Doxorubicin—DHCR7—uterine cervix—uterine cancer	0.000113	0.00595	CbGeAlD
Doxorubicin—NDUFS2—renal system—uterine cancer	0.000112	0.00593	CbGeAlD
Doxorubicin—AURKA—uterus—uterine cancer	0.000112	0.00593	CbGeAlD
Doxorubicin—CBR1—myometrium—uterine cancer	0.000112	0.00592	CbGeAlD
Doxorubicin—NDUFS3—renal system—uterine cancer	0.000111	0.00586	CbGeAlD
Doxorubicin—AKR1C3—myometrium—uterine cancer	0.000111	0.00584	CbGeAlD
Doxorubicin—AKR1A1—female gonad—uterine cancer	0.000109	0.00574	CbGeAlD
Doxorubicin—NDUFS2—endometrium—uterine cancer	0.000109	0.00574	CbGeAlD
Doxorubicin—NDUFS7—female reproductive system—uterine cancer	0.000108	0.00573	CbGeAlD
Doxorubicin—AKR1A1—vagina—uterine cancer	0.000108	0.00571	CbGeAlD
Doxorubicin—NDUFS3—endometrium—uterine cancer	0.000107	0.00567	CbGeAlD
Doxorubicin—NDUFS2—mammalian vulva—uterine cancer	0.000105	0.00555	CbGeAlD
Doxorubicin—NDUFS3—mammalian vulva—uterine cancer	0.000104	0.00548	CbGeAlD
Doxorubicin—YWHAG—uterine cervix—uterine cancer	0.000103	0.00546	CbGeAlD
Doxorubicin—ABCC6—renal system—uterine cancer	0.000103	0.00543	CbGeAlD
Doxorubicin—ABCC6—Podofilox—Etoposide—uterine cancer	0.000102	0.154	CbGdCrCtD
Doxorubicin—POR—myometrium—uterine cancer	0.000101	0.00534	CbGeAlD
Doxorubicin—AURKA—female reproductive system—uterine cancer	0.000101	0.00533	CbGeAlD
Doxorubicin—XDH—uterine cervix—uterine cancer	0.000101	0.00533	CbGeAlD
Doxorubicin—YWHAG—smooth muscle tissue—uterine cancer	0.0001	0.00531	CbGeAlD
Doxorubicin—NDUFS2—uterus—uterine cancer	0.0001	0.00529	CbGeAlD
Doxorubicin—NDUFS3—uterus—uterine cancer	9.88e-05	0.00522	CbGeAlD
Doxorubicin—NDUFS7—female gonad—uterine cancer	9.87e-05	0.00522	CbGeAlD
Doxorubicin—DHCR7—mammalian vulva—uterine cancer	9.85e-05	0.00521	CbGeAlD
Doxorubicin—YWHAG—decidua—uterine cancer	9.84e-05	0.0052	CbGeAlD
Doxorubicin—NDUFS7—vagina—uterine cancer	9.81e-05	0.00519	CbGeAlD
Doxorubicin—YWHAG—renal system—uterine cancer	9.67e-05	0.00511	CbGeAlD
Doxorubicin—XDH—renal system—uterine cancer	9.43e-05	0.00498	CbGeAlD
Doxorubicin—TOP2A—myometrium—uterine cancer	9.41e-05	0.00497	CbGeAlD
Doxorubicin—ABCB8—lymph node—uterine cancer	9.4e-05	0.00497	CbGeAlD
Doxorubicin—YWHAG—endometrium—uterine cancer	9.35e-05	0.00494	CbGeAlD
Doxorubicin—RALBP1—uterine cervix—uterine cancer	9.33e-05	0.00493	CbGeAlD
Doxorubicin—NOS3—epithelium—uterine cancer	9.26e-05	0.00489	CbGeAlD
Doxorubicin—AURKA—female gonad—uterine cancer	9.18e-05	0.00485	CbGeAlD
Doxorubicin—CBR3—Teniposide—Etoposide—uterine cancer	9.16e-05	0.139	CbGdCrCtD
Doxorubicin—AURKA—vagina—uterine cancer	9.12e-05	0.00482	CbGeAlD
Doxorubicin—XDH—endometrium—uterine cancer	9.11e-05	0.00482	CbGeAlD
Doxorubicin—RALBP1—smooth muscle tissue—uterine cancer	9.07e-05	0.00479	CbGeAlD
Doxorubicin—NOS1—female reproductive system—uterine cancer	9.05e-05	0.00478	CbGeAlD
Doxorubicin—CBR3—lymph node—uterine cancer	9.04e-05	0.00478	CbGeAlD
Doxorubicin—YWHAG—mammalian vulva—uterine cancer	9.04e-05	0.00478	CbGeAlD
Doxorubicin—NDUFS2—female reproductive system—uterine cancer	8.99e-05	0.00475	CbGeAlD
Doxorubicin—NQO1—myometrium—uterine cancer	8.97e-05	0.00474	CbGeAlD
Doxorubicin—NOS3—smooth muscle tissue—uterine cancer	8.92e-05	0.00471	CbGeAlD
Doxorubicin—RALBP1—decidua—uterine cancer	8.89e-05	0.0047	CbGeAlD
Doxorubicin—AKR1C3—Podofilox—Etoposide—uterine cancer	8.89e-05	0.135	CbGdCrCtD
Doxorubicin—NDUFS3—female reproductive system—uterine cancer	8.88e-05	0.00469	CbGeAlD
Doxorubicin—XDH—mammalian vulva—uterine cancer	8.82e-05	0.00466	CbGeAlD
Doxorubicin—RALBP1—renal system—uterine cancer	8.73e-05	0.00461	CbGeAlD
Doxorubicin—CBR1—uterine cervix—uterine cancer	8.71e-05	0.0046	CbGeAlD
Doxorubicin—YWHAG—uterus—uterine cancer	8.61e-05	0.00455	CbGeAlD
Doxorubicin—AKR1C3—uterine cervix—uterine cancer	8.6e-05	0.00455	CbGeAlD
Doxorubicin—NOS3—renal system—uterine cancer	8.59e-05	0.00454	CbGeAlD
Doxorubicin—CBR3—Fluorometholone—Medroxyprogesterone Acetate—uterine cancer	8.45e-05	0.128	CbGdCrCtD
Doxorubicin—RALBP1—endometrium—uterine cancer	8.44e-05	0.00446	CbGeAlD
Doxorubicin—DHCR7—female reproductive system—uterine cancer	8.44e-05	0.00446	CbGeAlD
Doxorubicin—AKR1C3—smooth muscle tissue—uterine cancer	8.36e-05	0.00442	CbGeAlD
Doxorubicin—CBR1—decidua—uterine cancer	8.3e-05	0.00439	CbGeAlD
Doxorubicin—AKR1C3—decidua—uterine cancer	8.2e-05	0.00433	CbGeAlD
Doxorubicin—NDUFS2—female gonad—uterine cancer	8.18e-05	0.00432	CbGeAlD
Doxorubicin—RALBP1—mammalian vulva—uterine cancer	8.16e-05	0.00431	CbGeAlD
Doxorubicin—CBR1—renal system—uterine cancer	8.15e-05	0.00431	CbGeAlD
Doxorubicin—NDUFS2—vagina—uterine cancer	8.13e-05	0.0043	CbGeAlD
Doxorubicin—NDUFS3—female gonad—uterine cancer	8.08e-05	0.00427	CbGeAlD
Doxorubicin—NDUFS3—vagina—uterine cancer	8.03e-05	0.00424	CbGeAlD
Doxorubicin—ABCC10—myometrium—uterine cancer	8.01e-05	0.00423	CbGeAlD
Doxorubicin—CBR1—endometrium—uterine cancer	7.88e-05	0.00416	CbGeAlD
Doxorubicin—POR—uterine cervix—uterine cancer	7.86e-05	0.00415	CbGeAlD
Doxorubicin—AKR1C3—endometrium—uterine cancer	7.78e-05	0.00411	CbGeAlD
Doxorubicin—RALBP1—uterus—uterine cancer	7.78e-05	0.00411	CbGeAlD
Doxorubicin—YWHAG—female reproductive system—uterine cancer	7.74e-05	0.00409	CbGeAlD
Doxorubicin—DHCR7—female gonad—uterine cancer	7.68e-05	0.00406	CbGeAlD
Doxorubicin—DHCR7—vagina—uterine cancer	7.63e-05	0.00403	CbGeAlD
Doxorubicin—CBR1—mammalian vulva—uterine cancer	7.62e-05	0.00403	CbGeAlD
Doxorubicin—XDH—female reproductive system—uterine cancer	7.55e-05	0.00399	CbGeAlD
Doxorubicin—AKR1C3—mammalian vulva—uterine cancer	7.53e-05	0.00398	CbGeAlD
Doxorubicin—POR—decidua—uterine cancer	7.48e-05	0.00396	CbGeAlD
Doxorubicin—TOP2A—uterine cervix—uterine cancer	7.32e-05	0.00387	CbGeAlD
Doxorubicin—CBR1—uterus—uterine cancer	7.26e-05	0.00384	CbGeAlD
Doxorubicin—AKR1C3—uterus—uterine cancer	7.17e-05	0.00379	CbGeAlD
Doxorubicin—POR—endometrium—uterine cancer	7.11e-05	0.00376	CbGeAlD
Doxorubicin—YWHAG—female gonad—uterine cancer	7.04e-05	0.00372	CbGeAlD
Doxorubicin—NQO1—epithelium—uterine cancer	7.04e-05	0.00372	CbGeAlD
Doxorubicin—YWHAG—vagina—uterine cancer	7e-05	0.0037	CbGeAlD
Doxorubicin—RALBP1—female reproductive system—uterine cancer	6.99e-05	0.00369	CbGeAlD
Doxorubicin—AKR1A1—lymph node—uterine cancer	6.98e-05	0.00369	CbGeAlD
Doxorubicin—NQO1—uterine cervix—uterine cancer	6.98e-05	0.00369	CbGeAlD
Doxorubicin—TOP2A—decidua—uterine cancer	6.98e-05	0.00369	CbGeAlD
Doxorubicin—NOS3—female reproductive system—uterine cancer	6.88e-05	0.00363	CbGeAlD
Doxorubicin—POR—mammalian vulva—uterine cancer	6.87e-05	0.00363	CbGeAlD
Doxorubicin—XDH—vagina—uterine cancer	6.83e-05	0.00361	CbGeAlD
Doxorubicin—NQO1—smooth muscle tissue—uterine cancer	6.78e-05	0.00358	CbGeAlD
Doxorubicin—NQO1—decidua—uterine cancer	6.65e-05	0.00351	CbGeAlD
Doxorubicin—TOP2A—endometrium—uterine cancer	6.62e-05	0.0035	CbGeAlD
Doxorubicin—NQO1—renal system—uterine cancer	6.53e-05	0.00345	CbGeAlD
Doxorubicin—CBR1—female reproductive system—uterine cancer	6.53e-05	0.00345	CbGeAlD
Doxorubicin—TOP2A—mammalian vulva—uterine cancer	6.41e-05	0.00339	CbGeAlD
Doxorubicin—RALBP1—female gonad—uterine cancer	6.36e-05	0.00336	CbGeAlD
Doxorubicin—NDUFS7—lymph node—uterine cancer	6.35e-05	0.00335	CbGeAlD
Doxorubicin—RALBP1—vagina—uterine cancer	6.32e-05	0.00334	CbGeAlD
Doxorubicin—NQO1—endometrium—uterine cancer	6.31e-05	0.00334	CbGeAlD
Doxorubicin—ABCC10—uterine cervix—uterine cancer	6.23e-05	0.00329	CbGeAlD
Doxorubicin—NOS3—vagina—uterine cancer	6.22e-05	0.00329	CbGeAlD
Doxorubicin—NQO1—mammalian vulva—uterine cancer	6.11e-05	0.00323	CbGeAlD
Doxorubicin—TOP2A—uterus—uterine cancer	6.1e-05	0.00323	CbGeAlD
Doxorubicin—ABCC3—decidua—uterine cancer	5.97e-05	0.00315	CbGeAlD
Doxorubicin—ABCC10—decidua—uterine cancer	5.94e-05	0.00314	CbGeAlD
Doxorubicin—CBR1—female gonad—uterine cancer	5.94e-05	0.00314	CbGeAlD
Doxorubicin—CBR1—vagina—uterine cancer	5.9e-05	0.00312	CbGeAlD
Doxorubicin—AURKA—lymph node—uterine cancer	5.9e-05	0.00312	CbGeAlD
Doxorubicin—AKR1C3—female gonad—uterine cancer	5.87e-05	0.0031	CbGeAlD
Doxorubicin—ABCC3—renal system—uterine cancer	5.86e-05	0.0031	CbGeAlD
Doxorubicin—ABCC10—renal system—uterine cancer	5.83e-05	0.00308	CbGeAlD
Doxorubicin—AKR1C3—vagina—uterine cancer	5.83e-05	0.00308	CbGeAlD
Doxorubicin—NQO1—uterus—uterine cancer	5.82e-05	0.00307	CbGeAlD
Doxorubicin—ABCC1—myometrium—uterine cancer	5.67e-05	0.00299	CbGeAlD
Doxorubicin—ABCC10—endometrium—uterine cancer	5.64e-05	0.00298	CbGeAlD
Doxorubicin—ABCC10—mammalian vulva—uterine cancer	5.45e-05	0.00288	CbGeAlD
Doxorubicin—POR—female gonad—uterine cancer	5.36e-05	0.00283	CbGeAlD
Doxorubicin—POR—vagina—uterine cancer	5.32e-05	0.00281	CbGeAlD
Doxorubicin—NDUFS2—lymph node—uterine cancer	5.26e-05	0.00278	CbGeAlD
Doxorubicin—NQO1—female reproductive system—uterine cancer	5.23e-05	0.00276	CbGeAlD
Doxorubicin—ABCC10—uterus—uterine cancer	5.2e-05	0.00275	CbGeAlD
Doxorubicin—NDUFS3—lymph node—uterine cancer	5.19e-05	0.00275	CbGeAlD
Doxorubicin—TOP2A—female gonad—uterine cancer	4.99e-05	0.00264	CbGeAlD
Doxorubicin—TOP2A—vagina—uterine cancer	4.96e-05	0.00262	CbGeAlD
Doxorubicin—DHCR7—lymph node—uterine cancer	4.94e-05	0.00261	CbGeAlD
Doxorubicin—AURKA—Teniposide—Etoposide—uterine cancer	4.83e-05	0.0731	CbGdCrCtD
Doxorubicin—CBR3—Daunorubicin—Epirubicin—uterine cancer	4.78e-05	0.0723	CbGdCrCtD
Doxorubicin—CBR3—Idarubicin—Epirubicin—uterine cancer	4.78e-05	0.0723	CbGdCrCtD
Doxorubicin—CYP1B1—smooth muscle tissue—uterine cancer	4.76e-05	0.00252	CbGeAlD
Doxorubicin—NQO1—female gonad—uterine cancer	4.76e-05	0.00251	CbGeAlD
Doxorubicin—NQO1—vagina—uterine cancer	4.73e-05	0.0025	CbGeAlD
Doxorubicin—ABCC3—female reproductive system—uterine cancer	4.69e-05	0.00248	CbGeAlD
Doxorubicin—ABCG2—myometrium—uterine cancer	4.69e-05	0.00248	CbGeAlD
Doxorubicin—ABCC2—renal system—uterine cancer	4.68e-05	0.00247	CbGeAlD
Doxorubicin—ABCC10—female reproductive system—uterine cancer	4.67e-05	0.00247	CbGeAlD
Doxorubicin—CYP1B1—decidua—uterine cancer	4.67e-05	0.00247	CbGeAlD
Doxorubicin—CYP1B1—renal system—uterine cancer	4.59e-05	0.00242	CbGeAlD
Doxorubicin—YWHAG—lymph node—uterine cancer	4.53e-05	0.00239	CbGeAlD
Doxorubicin—ABCC1—uterine cervix—uterine cancer	4.41e-05	0.00233	CbGeAlD
Doxorubicin—ABCC3—female gonad—uterine cancer	4.27e-05	0.00226	CbGeAlD
Doxorubicin—ABCC10—female gonad—uterine cancer	4.25e-05	0.00225	CbGeAlD
Doxorubicin—ABCC10—vagina—uterine cancer	4.22e-05	0.00223	CbGeAlD
Doxorubicin—ABCC1—decidua—uterine cancer	4.2e-05	0.00222	CbGeAlD
Doxorubicin—RALBP1—lymph node—uterine cancer	4.09e-05	0.00216	CbGeAlD
Doxorubicin—CYP1B1—uterus—uterine cancer	4.09e-05	0.00216	CbGeAlD
Doxorubicin—NOS3—lymph node—uterine cancer	4.02e-05	0.00213	CbGeAlD
Doxorubicin—ABCC1—endometrium—uterine cancer	3.99e-05	0.00211	CbGeAlD
Doxorubicin—ABCC1—mammalian vulva—uterine cancer	3.86e-05	0.00204	CbGeAlD
Doxorubicin—CBR1—lymph node—uterine cancer	3.82e-05	0.00202	CbGeAlD
Doxorubicin—AKR1C3—lymph node—uterine cancer	3.77e-05	0.00199	CbGeAlD
Doxorubicin—ABCC2—female reproductive system—uterine cancer	3.75e-05	0.00198	CbGeAlD
Doxorubicin—ABCC1—uterus—uterine cancer	3.67e-05	0.00194	CbGeAlD
Doxorubicin—CYP1B1—female reproductive system—uterine cancer	3.67e-05	0.00194	CbGeAlD
Doxorubicin—ABCG2—uterine cervix—uterine cancer	3.65e-05	0.00193	CbGeAlD
Doxorubicin—ABCG2—decidua—uterine cancer	3.48e-05	0.00184	CbGeAlD
Doxorubicin—POR—lymph node—uterine cancer	3.44e-05	0.00182	CbGeAlD
Doxorubicin—CYP1B1—female gonad—uterine cancer	3.34e-05	0.00177	CbGeAlD
Doxorubicin—ABCG2—endometrium—uterine cancer	3.3e-05	0.00174	CbGeAlD
Doxorubicin—TOP2A—lymph node—uterine cancer	3.21e-05	0.0017	CbGeAlD
Doxorubicin—ABCG2—mammalian vulva—uterine cancer	3.19e-05	0.00169	CbGeAlD
Doxorubicin—CYP2B6—renal system—uterine cancer	3.15e-05	0.00166	CbGeAlD
Doxorubicin—NQO1—lymph node—uterine cancer	3.06e-05	0.00162	CbGeAlD
Doxorubicin—ABCG2—uterus—uterine cancer	3.04e-05	0.00161	CbGeAlD
Doxorubicin—ABCC1—female gonad—uterine cancer	3.01e-05	0.00159	CbGeAlD
Doxorubicin—ABCC1—vagina—uterine cancer	2.99e-05	0.00158	CbGeAlD
Doxorubicin—ABCC3—lymph node—uterine cancer	2.75e-05	0.00145	CbGeAlD
Doxorubicin—ABCC10—lymph node—uterine cancer	2.73e-05	0.00144	CbGeAlD
Doxorubicin—CYP2B6—female reproductive system—uterine cancer	2.52e-05	0.00133	CbGeAlD
Doxorubicin—AURKA—Daunorubicin—Epirubicin—uterine cancer	2.52e-05	0.0381	CbGdCrCtD
Doxorubicin—AURKA—Idarubicin—Epirubicin—uterine cancer	2.52e-05	0.0381	CbGdCrCtD
Doxorubicin—ABCG2—female gonad—uterine cancer	2.49e-05	0.00132	CbGeAlD
Doxorubicin—ABCG2—vagina—uterine cancer	2.47e-05	0.00131	CbGeAlD
Doxorubicin—CYP3A4—renal system—uterine cancer	2.38e-05	0.00126	CbGeAlD
Doxorubicin—CYP2D6—renal system—uterine cancer	2.34e-05	0.00124	CbGeAlD
Doxorubicin—ABCB1—myometrium—uterine cancer	2.31e-05	0.00122	CbGeAlD
Doxorubicin—CYP2B6—vagina—uterine cancer	2.28e-05	0.00121	CbGeAlD
Doxorubicin—ABCC2—lymph node—uterine cancer	2.19e-05	0.00116	CbGeAlD
Doxorubicin—CYP1B1—lymph node—uterine cancer	2.15e-05	0.00114	CbGeAlD
Doxorubicin—ABCC1—lymph node—uterine cancer	1.93e-05	0.00102	CbGeAlD
Doxorubicin—CYP3A4—female reproductive system—uterine cancer	1.9e-05	0.00101	CbGeAlD
Doxorubicin—CYP2D6—female reproductive system—uterine cancer	1.87e-05	0.000991	CbGeAlD
Doxorubicin—TOP2A—Podofilox—Etoposide—uterine cancer	1.84e-05	0.0279	CbGdCrCtD
Doxorubicin—TOP2A—Teniposide—Etoposide—uterine cancer	1.84e-05	0.0279	CbGdCrCtD
Doxorubicin—ABCB1—epithelium—uterine cancer	1.82e-05	0.000959	CbGeAlD
Doxorubicin—ABCB1—uterine cervix—uterine cancer	1.8e-05	0.000951	CbGeAlD
Doxorubicin—ABCB1—decidua—uterine cancer	1.71e-05	0.000906	CbGeAlD
Doxorubicin—CYP2D6—female gonad—uterine cancer	1.71e-05	0.000902	CbGeAlD
Doxorubicin—ABCB1—renal system—uterine cancer	1.68e-05	0.00089	CbGeAlD
Doxorubicin—ABCB1—endometrium—uterine cancer	1.63e-05	0.00086	CbGeAlD
Doxorubicin—ABCG2—lymph node—uterine cancer	1.6e-05	0.000845	CbGeAlD
Doxorubicin—ABCB1—mammalian vulva—uterine cancer	1.57e-05	0.000832	CbGeAlD
Doxorubicin—TOP2A—Methyltestosterone—Medroxyprogesterone Acetate—uterine cancer	1.5e-05	0.0228	CbGdCrCtD
Doxorubicin—ABCB1—uterus—uterine cancer	1.5e-05	0.000793	CbGeAlD
Doxorubicin—ABCB1—female reproductive system—uterine cancer	1.35e-05	0.000713	CbGeAlD
Doxorubicin—TOP2A—Methyltestosterone—Progesterone—uterine cancer	1.31e-05	0.0199	CbGdCrCtD
Doxorubicin—ABCB1—female gonad—uterine cancer	1.23e-05	0.000648	CbGeAlD
Doxorubicin—ABCB1—vagina—uterine cancer	1.22e-05	0.000645	CbGeAlD
Doxorubicin—Hepatic function abnormal—Epirubicin—uterine cancer	1.05e-05	0.000275	CcSEcCtD
Doxorubicin—Photosensitivity—Epirubicin—uterine cancer	1.04e-05	0.000273	CcSEcCtD
Doxorubicin—Dizziness—Progesterone—uterine cancer	1.04e-05	0.000272	CcSEcCtD
Doxorubicin—Angiopathy—Etoposide—uterine cancer	1.02e-05	0.000269	CcSEcCtD
Doxorubicin—Vascular purpura—Epirubicin—uterine cancer	1.02e-05	0.000268	CcSEcCtD
Doxorubicin—Immune system disorder—Etoposide—uterine cancer	1.02e-05	0.000267	CcSEcCtD
Doxorubicin—Asthenia—Medroxyprogesterone Acetate—uterine cancer	1.02e-05	0.000267	CcSEcCtD
Doxorubicin—Hepatic failure—Epirubicin—uterine cancer	1.02e-05	0.000267	CcSEcCtD
Doxorubicin—Eczema—Epirubicin—uterine cancer	1.02e-05	0.000267	CcSEcCtD
Doxorubicin—Mediastinal disorder—Etoposide—uterine cancer	1.02e-05	0.000267	CcSEcCtD
Doxorubicin—Eye pain—Epirubicin—uterine cancer	1.01e-05	0.000266	CcSEcCtD
Doxorubicin—Chills—Etoposide—uterine cancer	1.01e-05	0.000266	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Dactinomycin—uterine cancer	1.01e-05	0.000265	CcSEcCtD
Doxorubicin—Cardiac failure congestive—Epirubicin—uterine cancer	1.01e-05	0.000265	CcSEcCtD
Doxorubicin—Pruritus—Medroxyprogesterone Acetate—uterine cancer	1e-05	0.000264	CcSEcCtD
Doxorubicin—Alopecia—Etoposide—uterine cancer	9.96e-06	0.000262	CcSEcCtD
Doxorubicin—Vomiting—Progesterone—uterine cancer	9.96e-06	0.000261	CcSEcCtD
Doxorubicin—Renal failure acute—Epirubicin—uterine cancer	9.89e-06	0.00026	CcSEcCtD
Doxorubicin—Rash—Progesterone—uterine cancer	9.87e-06	0.000259	CcSEcCtD
Doxorubicin—Dermatitis—Progesterone—uterine cancer	9.86e-06	0.000259	CcSEcCtD
Doxorubicin—Headache—Progesterone—uterine cancer	9.81e-06	0.000258	CcSEcCtD
Doxorubicin—Hot flush—Epirubicin—uterine cancer	9.77e-06	0.000256	CcSEcCtD
Doxorubicin—Increased appetite—Epirubicin—uterine cancer	9.72e-06	0.000255	CcSEcCtD
Doxorubicin—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	9.71e-06	0.000255	CcSEcCtD
Doxorubicin—Menopausal symptoms—Epirubicin—uterine cancer	9.68e-06	0.000254	CcSEcCtD
Doxorubicin—Dermatitis exfoliative—Epirubicin—uterine cancer	9.68e-06	0.000254	CcSEcCtD
Doxorubicin—Decreased appetite—Dactinomycin—uterine cancer	9.62e-06	0.000253	CcSEcCtD
Doxorubicin—TOP2A—Idarubicin—Epirubicin—uterine cancer	9.61e-06	0.0146	CbGdCrCtD
Doxorubicin—TOP2A—Daunorubicin—Epirubicin—uterine cancer	9.61e-06	0.0146	CbGdCrCtD
Doxorubicin—Dysgeusia—Etoposide—uterine cancer	9.61e-06	0.000252	CcSEcCtD
Doxorubicin—Renal impairment—Epirubicin—uterine cancer	9.6e-06	0.000252	CcSEcCtD
Doxorubicin—Dermatitis bullous—Epirubicin—uterine cancer	9.56e-06	0.000251	CcSEcCtD
Doxorubicin—Fatigue—Dactinomycin—uterine cancer	9.54e-06	0.000251	CcSEcCtD
Doxorubicin—Back pain—Etoposide—uterine cancer	9.49e-06	0.000249	CcSEcCtD
Doxorubicin—Purpura—Epirubicin—uterine cancer	9.48e-06	0.000249	CcSEcCtD
Doxorubicin—Pain—Dactinomycin—uterine cancer	9.46e-06	0.000249	CcSEcCtD
Doxorubicin—Anaphylactoid reaction—Epirubicin—uterine cancer	9.44e-06	0.000248	CcSEcCtD
Doxorubicin—Muscle spasms—Etoposide—uterine cancer	9.44e-06	0.000248	CcSEcCtD
Doxorubicin—Dizziness—Medroxyprogesterone Acetate—uterine cancer	9.38e-06	0.000246	CcSEcCtD
Doxorubicin—Hypoglycaemia—Epirubicin—uterine cancer	9.36e-06	0.000246	CcSEcCtD
Doxorubicin—Cardiac failure—Epirubicin—uterine cancer	9.36e-06	0.000246	CcSEcCtD
Doxorubicin—Cerebrovascular accident—Epirubicin—uterine cancer	9.32e-06	0.000245	CcSEcCtD
Doxorubicin—Lethargy—Epirubicin—uterine cancer	9.32e-06	0.000245	CcSEcCtD
Doxorubicin—Nausea—Progesterone—uterine cancer	9.3e-06	0.000244	CcSEcCtD
Doxorubicin—Hyponatraemia—Epirubicin—uterine cancer	9.17e-06	0.000241	CcSEcCtD
Doxorubicin—Osteoarthritis—Epirubicin—uterine cancer	9.14e-06	0.00024	CcSEcCtD
Doxorubicin—Pain in extremity—Epirubicin—uterine cancer	9.14e-06	0.00024	CcSEcCtD
Doxorubicin—Diplopia—Epirubicin—uterine cancer	9.14e-06	0.00024	CcSEcCtD
Doxorubicin—Gastrointestinal haemorrhage—Epirubicin—uterine cancer	9.14e-06	0.00024	CcSEcCtD
Doxorubicin—Feeling abnormal—Dactinomycin—uterine cancer	9.12e-06	0.00024	CcSEcCtD
Doxorubicin—Ill-defined disorder—Etoposide—uterine cancer	9.11e-06	0.000239	CcSEcCtD
Doxorubicin—Anaemia—Etoposide—uterine cancer	9.07e-06	0.000238	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Dactinomycin—uterine cancer	9.05e-06	0.000238	CcSEcCtD
Doxorubicin—Vomiting—Medroxyprogesterone Acetate—uterine cancer	9.02e-06	0.000237	CcSEcCtD
Doxorubicin—Affect lability—Epirubicin—uterine cancer	8.99e-06	0.000236	CcSEcCtD
Doxorubicin—Migraine—Epirubicin—uterine cancer	8.99e-06	0.000236	CcSEcCtD
Doxorubicin—Rash—Medroxyprogesterone Acetate—uterine cancer	8.95e-06	0.000235	CcSEcCtD
Doxorubicin—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	8.94e-06	0.000235	CcSEcCtD
Doxorubicin—Headache—Medroxyprogesterone Acetate—uterine cancer	8.89e-06	0.000233	CcSEcCtD
Doxorubicin—Malaise—Etoposide—uterine cancer	8.85e-06	0.000232	CcSEcCtD
Doxorubicin—Face oedema—Epirubicin—uterine cancer	8.82e-06	0.000232	CcSEcCtD
Doxorubicin—Vertigo—Etoposide—uterine cancer	8.82e-06	0.000232	CcSEcCtD
Doxorubicin—Leukopenia—Etoposide—uterine cancer	8.78e-06	0.000231	CcSEcCtD
Doxorubicin—Body temperature increased—Dactinomycin—uterine cancer	8.75e-06	0.00023	CcSEcCtD
Doxorubicin—Abdominal pain—Dactinomycin—uterine cancer	8.75e-06	0.00023	CcSEcCtD
Doxorubicin—Cardiac arrest—Epirubicin—uterine cancer	8.69e-06	0.000228	CcSEcCtD
Doxorubicin—Mood swings—Epirubicin—uterine cancer	8.65e-06	0.000227	CcSEcCtD
Doxorubicin—Loss of consciousness—Etoposide—uterine cancer	8.63e-06	0.000227	CcSEcCtD
Doxorubicin—Ataxia—Epirubicin—uterine cancer	8.59e-06	0.000226	CcSEcCtD
Doxorubicin—Cough—Etoposide—uterine cancer	8.56e-06	0.000225	CcSEcCtD
Doxorubicin—Blood creatinine increased—Epirubicin—uterine cancer	8.56e-06	0.000225	CcSEcCtD
Doxorubicin—TOP2A—Norethindrone—Progesterone—uterine cancer	8.55e-06	0.0129	CbGdCrCtD
Doxorubicin—Convulsion—Etoposide—uterine cancer	8.5e-06	0.000223	CcSEcCtD
Doxorubicin—Dehydration—Epirubicin—uterine cancer	8.5e-06	0.000223	CcSEcCtD
Doxorubicin—Hypertension—Etoposide—uterine cancer	8.47e-06	0.000223	CcSEcCtD
Doxorubicin—Liver function test abnormal—Epirubicin—uterine cancer	8.43e-06	0.000222	CcSEcCtD
Doxorubicin—Nausea—Medroxyprogesterone Acetate—uterine cancer	8.43e-06	0.000221	CcSEcCtD
Doxorubicin—Dry skin—Epirubicin—uterine cancer	8.37e-06	0.00022	CcSEcCtD
Doxorubicin—Chest pain—Etoposide—uterine cancer	8.36e-06	0.000219	CcSEcCtD
Doxorubicin—Orthostatic hypotension—Epirubicin—uterine cancer	8.34e-06	0.000219	CcSEcCtD
Doxorubicin—Abdominal pain upper—Epirubicin—uterine cancer	8.34e-06	0.000219	CcSEcCtD
Doxorubicin—Hypokalaemia—Epirubicin—uterine cancer	8.31e-06	0.000218	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	8.3e-06	0.000218	CcSEcCtD
Doxorubicin—Discomfort—Etoposide—uterine cancer	8.26e-06	0.000217	CcSEcCtD
Doxorubicin—Breast disorder—Epirubicin—uterine cancer	8.26e-06	0.000217	CcSEcCtD
Doxorubicin—Aspartate aminotransferase increased—Epirubicin—uterine cancer	8.23e-06	0.000216	CcSEcCtD
Doxorubicin—Toxic epidermal necrolysis—Epirubicin—uterine cancer	8.23e-06	0.000216	CcSEcCtD
Doxorubicin—Nasopharyngitis—Epirubicin—uterine cancer	8.17e-06	0.000215	CcSEcCtD
Doxorubicin—Hypersensitivity—Dactinomycin—uterine cancer	8.15e-06	0.000214	CcSEcCtD
Doxorubicin—Gastritis—Epirubicin—uterine cancer	8.08e-06	0.000212	CcSEcCtD
Doxorubicin—Confusional state—Etoposide—uterine cancer	8.08e-06	0.000212	CcSEcCtD
Doxorubicin—Muscular weakness—Epirubicin—uterine cancer	8.06e-06	0.000212	CcSEcCtD
Doxorubicin—Alanine aminotransferase increased—Epirubicin—uterine cancer	8.06e-06	0.000212	CcSEcCtD
Doxorubicin—Anaphylactic shock—Etoposide—uterine cancer	8.01e-06	0.00021	CcSEcCtD
Doxorubicin—Infection—Etoposide—uterine cancer	7.96e-06	0.000209	CcSEcCtD
Doxorubicin—Abdominal distension—Epirubicin—uterine cancer	7.95e-06	0.000209	CcSEcCtD
Doxorubicin—Asthenia—Dactinomycin—uterine cancer	7.94e-06	0.000209	CcSEcCtD
Doxorubicin—Asthma—Epirubicin—uterine cancer	7.9e-06	0.000207	CcSEcCtD
Doxorubicin—Dysphagia—Epirubicin—uterine cancer	7.9e-06	0.000207	CcSEcCtD
Doxorubicin—Influenza—Epirubicin—uterine cancer	7.9e-06	0.000207	CcSEcCtD
Doxorubicin—ABCB1—lymph node—uterine cancer	7.89e-06	0.000417	CbGeAlD
Doxorubicin—Thrombocytopenia—Etoposide—uterine cancer	7.84e-06	0.000206	CcSEcCtD
Doxorubicin—Tachycardia—Etoposide—uterine cancer	7.82e-06	0.000205	CcSEcCtD
Doxorubicin—Eosinophilia—Epirubicin—uterine cancer	7.82e-06	0.000205	CcSEcCtD
Doxorubicin—Skin disorder—Etoposide—uterine cancer	7.78e-06	0.000204	CcSEcCtD
Doxorubicin—Hyperhidrosis—Etoposide—uterine cancer	7.74e-06	0.000203	CcSEcCtD
Doxorubicin—Pancreatitis—Epirubicin—uterine cancer	7.74e-06	0.000203	CcSEcCtD
Doxorubicin—Angina pectoris—Epirubicin—uterine cancer	7.69e-06	0.000202	CcSEcCtD
Doxorubicin—Anorexia—Etoposide—uterine cancer	7.63e-06	0.000201	CcSEcCtD
Doxorubicin—Bronchitis—Epirubicin—uterine cancer	7.59e-06	0.000199	CcSEcCtD
Doxorubicin—Diarrhoea—Dactinomycin—uterine cancer	7.57e-06	0.000199	CcSEcCtD
Doxorubicin—Pancytopenia—Epirubicin—uterine cancer	7.5e-06	0.000197	CcSEcCtD
Doxorubicin—Hypotension—Etoposide—uterine cancer	7.48e-06	0.000197	CcSEcCtD
Doxorubicin—Dysuria—Epirubicin—uterine cancer	7.38e-06	0.000194	CcSEcCtD
Doxorubicin—Neutropenia—Epirubicin—uterine cancer	7.38e-06	0.000194	CcSEcCtD
Doxorubicin—Upper respiratory tract infection—Epirubicin—uterine cancer	7.34e-06	0.000193	CcSEcCtD
Doxorubicin—Pollakiuria—Epirubicin—uterine cancer	7.29e-06	0.000192	CcSEcCtD
Doxorubicin—Photosensitivity reaction—Epirubicin—uterine cancer	7.21e-06	0.000189	CcSEcCtD
Doxorubicin—Paraesthesia—Etoposide—uterine cancer	7.19e-06	0.000189	CcSEcCtD
Doxorubicin—Weight increased—Epirubicin—uterine cancer	7.19e-06	0.000189	CcSEcCtD
Doxorubicin—Weight decreased—Epirubicin—uterine cancer	7.14e-06	0.000188	CcSEcCtD
Doxorubicin—Dyspnoea—Etoposide—uterine cancer	7.14e-06	0.000188	CcSEcCtD
Doxorubicin—Hyperglycaemia—Epirubicin—uterine cancer	7.12e-06	0.000187	CcSEcCtD
Doxorubicin—Somnolence—Etoposide—uterine cancer	7.12e-06	0.000187	CcSEcCtD
Doxorubicin—Pneumonia—Epirubicin—uterine cancer	7.08e-06	0.000186	CcSEcCtD
Doxorubicin—Infestation—Epirubicin—uterine cancer	7.04e-06	0.000185	CcSEcCtD
Doxorubicin—Infestation NOS—Epirubicin—uterine cancer	7.04e-06	0.000185	CcSEcCtD
Doxorubicin—Drowsiness—Epirubicin—uterine cancer	7.04e-06	0.000185	CcSEcCtD
Doxorubicin—Vomiting—Dactinomycin—uterine cancer	7.04e-06	0.000185	CcSEcCtD
Doxorubicin—Stevens-Johnson syndrome—Epirubicin—uterine cancer	6.98e-06	0.000183	CcSEcCtD
Doxorubicin—Rash—Dactinomycin—uterine cancer	6.98e-06	0.000183	CcSEcCtD
Doxorubicin—Decreased appetite—Etoposide—uterine cancer	6.96e-06	0.000183	CcSEcCtD
Doxorubicin—Renal failure—Epirubicin—uterine cancer	6.92e-06	0.000182	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Etoposide—uterine cancer	6.92e-06	0.000182	CcSEcCtD
Doxorubicin—Fatigue—Etoposide—uterine cancer	6.91e-06	0.000181	CcSEcCtD
Doxorubicin—Neuropathy peripheral—Epirubicin—uterine cancer	6.9e-06	0.000181	CcSEcCtD
Doxorubicin—Jaundice—Epirubicin—uterine cancer	6.86e-06	0.00018	CcSEcCtD
Doxorubicin—Stomatitis—Epirubicin—uterine cancer	6.86e-06	0.00018	CcSEcCtD
Doxorubicin—Constipation—Etoposide—uterine cancer	6.85e-06	0.00018	CcSEcCtD
Doxorubicin—Pain—Etoposide—uterine cancer	6.85e-06	0.00018	CcSEcCtD
Doxorubicin—Urinary tract infection—Epirubicin—uterine cancer	6.84e-06	0.00018	CcSEcCtD
Doxorubicin—Conjunctivitis—Epirubicin—uterine cancer	6.84e-06	0.00018	CcSEcCtD
Doxorubicin—TOP2A—Levonorgestrel—Progesterone—uterine cancer	6.8e-06	0.0103	CbGdCrCtD
Doxorubicin—Sweating—Epirubicin—uterine cancer	6.75e-06	0.000177	CcSEcCtD
Doxorubicin—Haematuria—Epirubicin—uterine cancer	6.71e-06	0.000176	CcSEcCtD
Doxorubicin—Hepatobiliary disease—Epirubicin—uterine cancer	6.66e-06	0.000175	CcSEcCtD
Doxorubicin—Epistaxis—Epirubicin—uterine cancer	6.64e-06	0.000174	CcSEcCtD
Doxorubicin—Sinusitis—Epirubicin—uterine cancer	6.6e-06	0.000173	CcSEcCtD
Doxorubicin—Feeling abnormal—Etoposide—uterine cancer	6.6e-06	0.000173	CcSEcCtD
Doxorubicin—Nausea—Dactinomycin—uterine cancer	6.57e-06	0.000173	CcSEcCtD
Doxorubicin—Agranulocytosis—Epirubicin—uterine cancer	6.57e-06	0.000173	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Etoposide—uterine cancer	6.55e-06	0.000172	CcSEcCtD
Doxorubicin—Bradycardia—Epirubicin—uterine cancer	6.43e-06	0.000169	CcSEcCtD
Doxorubicin—Urticaria—Etoposide—uterine cancer	6.36e-06	0.000167	CcSEcCtD
Doxorubicin—Haemoglobin—Epirubicin—uterine cancer	6.35e-06	0.000167	CcSEcCtD
Doxorubicin—Rhinitis—Epirubicin—uterine cancer	6.34e-06	0.000166	CcSEcCtD
Doxorubicin—Abdominal pain—Etoposide—uterine cancer	6.33e-06	0.000166	CcSEcCtD
Doxorubicin—Body temperature increased—Etoposide—uterine cancer	6.33e-06	0.000166	CcSEcCtD
Doxorubicin—Haemorrhage—Epirubicin—uterine cancer	6.32e-06	0.000166	CcSEcCtD
Doxorubicin—Hepatitis—Epirubicin—uterine cancer	6.32e-06	0.000166	CcSEcCtD
Doxorubicin—Hypoaesthesia—Epirubicin—uterine cancer	6.29e-06	0.000165	CcSEcCtD
Doxorubicin—Pharyngitis—Epirubicin—uterine cancer	6.27e-06	0.000165	CcSEcCtD
Doxorubicin—Urinary tract disorder—Epirubicin—uterine cancer	6.24e-06	0.000164	CcSEcCtD
Doxorubicin—Oedema peripheral—Epirubicin—uterine cancer	6.23e-06	0.000164	CcSEcCtD
Doxorubicin—Connective tissue disorder—Epirubicin—uterine cancer	6.21e-06	0.000163	CcSEcCtD
Doxorubicin—Urethral disorder—Epirubicin—uterine cancer	6.19e-06	0.000163	CcSEcCtD
Doxorubicin—Visual impairment—Epirubicin—uterine cancer	6.09e-06	0.00016	CcSEcCtD
Doxorubicin—Erythema multiforme—Epirubicin—uterine cancer	5.98e-06	0.000157	CcSEcCtD
Doxorubicin—Eye disorder—Epirubicin—uterine cancer	5.91e-06	0.000155	CcSEcCtD
Doxorubicin—Hypersensitivity—Etoposide—uterine cancer	5.9e-06	0.000155	CcSEcCtD
Doxorubicin—Tinnitus—Epirubicin—uterine cancer	5.89e-06	0.000155	CcSEcCtD
Doxorubicin—Cardiac disorder—Epirubicin—uterine cancer	5.87e-06	0.000154	CcSEcCtD
Doxorubicin—Flushing—Epirubicin—uterine cancer	5.87e-06	0.000154	CcSEcCtD
Doxorubicin—Asthenia—Etoposide—uterine cancer	5.75e-06	0.000151	CcSEcCtD
Doxorubicin—Angiopathy—Epirubicin—uterine cancer	5.73e-06	0.000151	CcSEcCtD
Doxorubicin—Immune system disorder—Epirubicin—uterine cancer	5.71e-06	0.00015	CcSEcCtD
Doxorubicin—Mediastinal disorder—Epirubicin—uterine cancer	5.7e-06	0.00015	CcSEcCtD
Doxorubicin—Chills—Epirubicin—uterine cancer	5.67e-06	0.000149	CcSEcCtD
Doxorubicin—Pruritus—Etoposide—uterine cancer	5.67e-06	0.000149	CcSEcCtD
Doxorubicin—Arrhythmia—Epirubicin—uterine cancer	5.65e-06	0.000148	CcSEcCtD
Doxorubicin—Alopecia—Epirubicin—uterine cancer	5.58e-06	0.000147	CcSEcCtD
Doxorubicin—Mental disorder—Epirubicin—uterine cancer	5.54e-06	0.000145	CcSEcCtD
Doxorubicin—Erythema—Epirubicin—uterine cancer	5.5e-06	0.000144	CcSEcCtD
Doxorubicin—Malnutrition—Epirubicin—uterine cancer	5.5e-06	0.000144	CcSEcCtD
Doxorubicin—Diarrhoea—Etoposide—uterine cancer	5.48e-06	0.000144	CcSEcCtD
Doxorubicin—Flatulence—Epirubicin—uterine cancer	5.42e-06	0.000142	CcSEcCtD
Doxorubicin—Tension—Epirubicin—uterine cancer	5.4e-06	0.000142	CcSEcCtD
Doxorubicin—Dysgeusia—Epirubicin—uterine cancer	5.39e-06	0.000142	CcSEcCtD
Doxorubicin—Nervousness—Epirubicin—uterine cancer	5.34e-06	0.00014	CcSEcCtD
Doxorubicin—Back pain—Epirubicin—uterine cancer	5.32e-06	0.00014	CcSEcCtD
Doxorubicin—Dizziness—Etoposide—uterine cancer	5.3e-06	0.000139	CcSEcCtD
Doxorubicin—Muscle spasms—Epirubicin—uterine cancer	5.29e-06	0.000139	CcSEcCtD
Doxorubicin—Vision blurred—Epirubicin—uterine cancer	5.18e-06	0.000136	CcSEcCtD
Doxorubicin—Ill-defined disorder—Epirubicin—uterine cancer	5.1e-06	0.000134	CcSEcCtD
Doxorubicin—Vomiting—Etoposide—uterine cancer	5.09e-06	0.000134	CcSEcCtD
Doxorubicin—Anaemia—Epirubicin—uterine cancer	5.08e-06	0.000134	CcSEcCtD
Doxorubicin—Agitation—Epirubicin—uterine cancer	5.06e-06	0.000133	CcSEcCtD
Doxorubicin—Rash—Etoposide—uterine cancer	5.05e-06	0.000133	CcSEcCtD
Doxorubicin—Dermatitis—Etoposide—uterine cancer	5.05e-06	0.000133	CcSEcCtD
Doxorubicin—Headache—Etoposide—uterine cancer	5.02e-06	0.000132	CcSEcCtD
Doxorubicin—Malaise—Epirubicin—uterine cancer	4.96e-06	0.00013	CcSEcCtD
Doxorubicin—Vertigo—Epirubicin—uterine cancer	4.94e-06	0.00013	CcSEcCtD
Doxorubicin—Syncope—Epirubicin—uterine cancer	4.93e-06	0.00013	CcSEcCtD
Doxorubicin—Leukopenia—Epirubicin—uterine cancer	4.92e-06	0.000129	CcSEcCtD
Doxorubicin—Palpitations—Epirubicin—uterine cancer	4.86e-06	0.000128	CcSEcCtD
Doxorubicin—Loss of consciousness—Epirubicin—uterine cancer	4.84e-06	0.000127	CcSEcCtD
Doxorubicin—Cough—Epirubicin—uterine cancer	4.8e-06	0.000126	CcSEcCtD
Doxorubicin—Convulsion—Epirubicin—uterine cancer	4.77e-06	0.000125	CcSEcCtD
Doxorubicin—Nausea—Etoposide—uterine cancer	4.76e-06	0.000125	CcSEcCtD
Doxorubicin—Hypertension—Epirubicin—uterine cancer	4.75e-06	0.000125	CcSEcCtD
Doxorubicin—Arthralgia—Epirubicin—uterine cancer	4.68e-06	0.000123	CcSEcCtD
Doxorubicin—Chest pain—Epirubicin—uterine cancer	4.68e-06	0.000123	CcSEcCtD
Doxorubicin—Myalgia—Epirubicin—uterine cancer	4.68e-06	0.000123	CcSEcCtD
Doxorubicin—Anxiety—Epirubicin—uterine cancer	4.67e-06	0.000123	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	4.65e-06	0.000122	CcSEcCtD
Doxorubicin—Discomfort—Epirubicin—uterine cancer	4.63e-06	0.000122	CcSEcCtD
Doxorubicin—Dry mouth—Epirubicin—uterine cancer	4.58e-06	0.00012	CcSEcCtD
Doxorubicin—Confusional state—Epirubicin—uterine cancer	4.53e-06	0.000119	CcSEcCtD
Doxorubicin—Oedema—Epirubicin—uterine cancer	4.49e-06	0.000118	CcSEcCtD
Doxorubicin—Anaphylactic shock—Epirubicin—uterine cancer	4.49e-06	0.000118	CcSEcCtD
Doxorubicin—Infection—Epirubicin—uterine cancer	4.46e-06	0.000117	CcSEcCtD
Doxorubicin—Shock—Epirubicin—uterine cancer	4.42e-06	0.000116	CcSEcCtD
Doxorubicin—Nervous system disorder—Epirubicin—uterine cancer	4.4e-06	0.000116	CcSEcCtD
Doxorubicin—Thrombocytopenia—Epirubicin—uterine cancer	4.4e-06	0.000115	CcSEcCtD
Doxorubicin—Tachycardia—Epirubicin—uterine cancer	4.38e-06	0.000115	CcSEcCtD
Doxorubicin—Skin disorder—Epirubicin—uterine cancer	4.36e-06	0.000115	CcSEcCtD
Doxorubicin—Hyperhidrosis—Epirubicin—uterine cancer	4.34e-06	0.000114	CcSEcCtD
Doxorubicin—Anorexia—Epirubicin—uterine cancer	4.28e-06	0.000112	CcSEcCtD
Doxorubicin—Hypotension—Epirubicin—uterine cancer	4.2e-06	0.00011	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Epirubicin—uterine cancer	4.09e-06	0.000107	CcSEcCtD
Doxorubicin—Insomnia—Epirubicin—uterine cancer	4.06e-06	0.000107	CcSEcCtD
Doxorubicin—Paraesthesia—Epirubicin—uterine cancer	4.03e-06	0.000106	CcSEcCtD
Doxorubicin—Dyspnoea—Epirubicin—uterine cancer	4e-06	0.000105	CcSEcCtD
Doxorubicin—Somnolence—Epirubicin—uterine cancer	3.99e-06	0.000105	CcSEcCtD
Doxorubicin—Dyspepsia—Epirubicin—uterine cancer	3.95e-06	0.000104	CcSEcCtD
Doxorubicin—Decreased appetite—Epirubicin—uterine cancer	3.9e-06	0.000103	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Epirubicin—uterine cancer	3.88e-06	0.000102	CcSEcCtD
Doxorubicin—Fatigue—Epirubicin—uterine cancer	3.87e-06	0.000102	CcSEcCtD
Doxorubicin—Constipation—Epirubicin—uterine cancer	3.84e-06	0.000101	CcSEcCtD
Doxorubicin—Pain—Epirubicin—uterine cancer	3.84e-06	0.000101	CcSEcCtD
Doxorubicin—Feeling abnormal—Epirubicin—uterine cancer	3.7e-06	9.72e-05	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Epirubicin—uterine cancer	3.67e-06	9.64e-05	CcSEcCtD
Doxorubicin—Urticaria—Epirubicin—uterine cancer	3.57e-06	9.37e-05	CcSEcCtD
Doxorubicin—Abdominal pain—Epirubicin—uterine cancer	3.55e-06	9.32e-05	CcSEcCtD
Doxorubicin—Body temperature increased—Epirubicin—uterine cancer	3.55e-06	9.32e-05	CcSEcCtD
Doxorubicin—Hypersensitivity—Epirubicin—uterine cancer	3.31e-06	8.69e-05	CcSEcCtD
Doxorubicin—Asthenia—Epirubicin—uterine cancer	3.22e-06	8.46e-05	CcSEcCtD
Doxorubicin—Pruritus—Epirubicin—uterine cancer	3.18e-06	8.34e-05	CcSEcCtD
Doxorubicin—Diarrhoea—Epirubicin—uterine cancer	3.07e-06	8.07e-05	CcSEcCtD
Doxorubicin—Dizziness—Epirubicin—uterine cancer	2.97e-06	7.8e-05	CcSEcCtD
Doxorubicin—Vomiting—Epirubicin—uterine cancer	2.85e-06	7.5e-05	CcSEcCtD
Doxorubicin—Rash—Epirubicin—uterine cancer	2.83e-06	7.44e-05	CcSEcCtD
Doxorubicin—Dermatitis—Epirubicin—uterine cancer	2.83e-06	7.43e-05	CcSEcCtD
Doxorubicin—Headache—Epirubicin—uterine cancer	2.81e-06	7.39e-05	CcSEcCtD
Doxorubicin—Nausea—Epirubicin—uterine cancer	2.67e-06	7e-05	CcSEcCtD
Doxorubicin—CYP1B1—Metabolism—CYP11A1—uterine cancer	1.75e-06	8.07e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—RRM2—uterine cancer	1.74e-06	8.02e-05	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—KRAS—uterine cancer	1.73e-06	7.97e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.71e-06	7.89e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—SOCS3—uterine cancer	1.71e-06	7.88e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—AKR1C3—uterine cancer	1.71e-06	7.88e-05	CbGpPWpGaD
Doxorubicin—NDUFS2—Metabolism—PIK3CA—uterine cancer	1.71e-06	7.87e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—STK11—uterine cancer	1.7e-06	7.83e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—CYP19A1—uterine cancer	1.7e-06	7.83e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—DCN—uterine cancer	1.69e-06	7.79e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—FGFR2—uterine cancer	1.69e-06	7.78e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—CTNNB1—uterine cancer	1.68e-06	7.71e-05	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—AKT1—uterine cancer	1.67e-06	7.71e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	1.67e-06	7.69e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.67e-06	7.67e-05	CbGpPWpGaD
Doxorubicin—NOS1—Disease—NRAS—uterine cancer	1.66e-06	7.66e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—AKR1C3—uterine cancer	1.65e-06	7.62e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—ERBB2—uterine cancer	1.65e-06	7.59e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—MTHFR—uterine cancer	1.64e-06	7.57e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CDKN2B—uterine cancer	1.64e-06	7.55e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—PTEN—uterine cancer	1.63e-06	7.52e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.6e-06	7.35e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—CYP11A1—uterine cancer	1.59e-06	7.34e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—IGF1R—uterine cancer	1.59e-06	7.33e-05	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—PIK3CA—uterine cancer	1.59e-06	7.32e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.59e-06	7.31e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—EP300—uterine cancer	1.56e-06	7.17e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	1.55e-06	7.13e-05	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—TP53—uterine cancer	1.54e-06	7.09e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—POLD1—uterine cancer	1.53e-06	7.05e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—CDKN1B—uterine cancer	1.53e-06	7.03e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.52e-06	7.01e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—ERBB2—uterine cancer	1.52e-06	6.98e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—AKR1C3—uterine cancer	1.51e-06	6.93e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—SMAD3—uterine cancer	1.5e-06	6.89e-05	CbGpPWpGaD
Doxorubicin—NDUFS7—Metabolism—AKT1—uterine cancer	1.48e-06	6.84e-05	CbGpPWpGaD
Doxorubicin—NDUFS3—Metabolism—AKT1—uterine cancer	1.48e-06	6.84e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—VEGFA—uterine cancer	1.47e-06	6.79e-05	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—HRAS—uterine cancer	1.47e-06	6.78e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	1.46e-06	6.73e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—NRAS—uterine cancer	1.46e-06	6.71e-05	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism—PIK3CA—uterine cancer	1.45e-06	6.69e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—ESR1—uterine cancer	1.45e-06	6.66e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—CTNNB1—uterine cancer	1.44e-06	6.64e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—STAR—uterine cancer	1.44e-06	6.63e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—AKR1B1—uterine cancer	1.44e-06	6.63e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—AKR1C1—uterine cancer	1.43e-06	6.6e-05	CbGpPWpGaD
Doxorubicin—NOS1—Disease—KRAS—uterine cancer	1.43e-06	6.59e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—FGFR2—uterine cancer	1.43e-06	6.57e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CDKN2B—uterine cancer	1.43e-06	6.57e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	1.43e-06	6.56e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—PTEN—uterine cancer	1.41e-06	6.47e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—CDKN1B—uterine cancer	1.4e-06	6.46e-05	CbGpPWpGaD
Doxorubicin—NDUFS2—Metabolism—AKT1—uterine cancer	1.4e-06	6.43e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	1.36e-06	6.26e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—AKR1B1—uterine cancer	1.36e-06	6.25e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—STAR—uterine cancer	1.36e-06	6.25e-05	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—PIK3CA—uterine cancer	1.36e-06	6.24e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—EP300—uterine cancer	1.34e-06	6.17e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—MTHFR—uterine cancer	1.33e-06	6.14e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—STK11—uterine cancer	1.33e-06	6.14e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—CYP19A1—uterine cancer	1.33e-06	6.14e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—CTNNB1—uterine cancer	1.33e-06	6.1e-05	CbGpPWpGaD
Doxorubicin—NOS1—Disease—PIK3CA—uterine cancer	1.31e-06	6.05e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—SMAD3—uterine cancer	1.3e-06	6e-05	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—AKT1—uterine cancer	1.3e-06	5.98e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—PTEN—uterine cancer	1.29e-06	5.95e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—STK11—uterine cancer	1.29e-06	5.93e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—CYP19A1—uterine cancer	1.29e-06	5.93e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	1.29e-06	5.93e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—ERBB2—uterine cancer	1.28e-06	5.89e-05	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle—TP53—uterine cancer	1.28e-06	5.89e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—MTHFR—uterine cancer	1.28e-06	5.88e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—RRM2—uterine cancer	1.28e-06	5.88e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CCL2—uterine cancer	1.27e-06	5.86e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—NRAS—uterine cancer	1.25e-06	5.77e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—KRAS—uterine cancer	1.25e-06	5.77e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.25e-06	5.76e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—FGFR2—uterine cancer	1.24e-06	5.72e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—DCN—uterine cancer	1.24e-06	5.71e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—EP300—uterine cancer	1.23e-06	5.67e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—SRD5A2—uterine cancer	1.23e-06	5.65e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—NDUFB11—uterine cancer	1.23e-06	5.65e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—ESR1—uterine cancer	1.22e-06	5.62e-05	CbGpPWpGaD
Doxorubicin—NOS1—Disease—HRAS—uterine cancer	1.22e-06	5.6e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.21e-06	5.57e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—MTHFR—uterine cancer	1.2e-06	5.51e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.19e-06	5.49e-05	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism—AKT1—uterine cancer	1.19e-06	5.47e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—CDKN1B—uterine cancer	1.19e-06	5.46e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.17e-06	5.41e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—STK11—uterine cancer	1.17e-06	5.4e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—CYP19A1—uterine cancer	1.17e-06	5.4e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CYP11A1—uterine cancer	1.17e-06	5.38e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.15e-06	5.31e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—NRAS—uterine cancer	1.15e-06	5.31e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—PIK3CA—uterine cancer	1.15e-06	5.3e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—POLD1—uterine cancer	1.13e-06	5.2e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.13e-06	5.19e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—PTEN—uterine cancer	1.12e-06	5.16e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—CTNNB1—uterine cancer	1.12e-06	5.16e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—TP53—uterine cancer	1.11e-06	5.13e-05	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—AKT1—uterine cancer	1.11e-06	5.1e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—AKR1C3—uterine cancer	1.1e-06	5.08e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	1.09e-06	5.04e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—PTEN—uterine cancer	1.09e-06	5.03e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—PTEN—uterine cancer	1.08e-06	4.98e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—KRAS—uterine cancer	1.08e-06	4.97e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CCL2—uterine cancer	1.08e-06	4.95e-05	CbGpPWpGaD
Doxorubicin—NOS1—Disease—AKT1—uterine cancer	1.07e-06	4.95e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—EP300—uterine cancer	1.07e-06	4.92e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—HRAS—uterine cancer	1.07e-06	4.91e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—POLD1—uterine cancer	1.06e-06	4.9e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—ERBB2—uterine cancer	1.06e-06	4.88e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—AKR1C1—uterine cancer	1.06e-06	4.87e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—EP300—uterine cancer	1.04e-06	4.79e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—EP300—uterine cancer	1.03e-06	4.75e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CXCL8—uterine cancer	1.01e-06	4.63e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—PTEN—uterine cancer	1.01e-06	4.63e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	1.01e-06	4.63e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—MTHFR—uterine cancer	1e-06	4.61e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—AKR1C1—uterine cancer	9.96e-07	4.59e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—KRAS—uterine cancer	9.92e-07	4.57e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—PIK3CA—uterine cancer	9.92e-07	4.57e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CDKN1B—uterine cancer	9.83e-07	4.52e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—NRAS—uterine cancer	9.74e-07	4.48e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	9.73e-07	4.48e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—MTHFR—uterine cancer	9.69e-07	4.46e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—EP300—uterine cancer	9.59e-07	4.42e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—RRM2—uterine cancer	9.42e-07	4.34e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—AKT1—uterine cancer	9.41e-07	4.33e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CTNNB1—uterine cancer	9.28e-07	4.27e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—HRAS—uterine cancer	9.18e-07	4.22e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—DCN—uterine cancer	9.15e-07	4.21e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PTEN—uterine cancer	9.14e-07	4.21e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—PIK3CA—uterine cancer	9.11e-07	4.2e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—PTEN—uterine cancer	9.05e-07	4.17e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—ERBB2—uterine cancer	8.96e-07	4.13e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—RRM2—uterine cancer	8.88e-07	4.09e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—AKR1B1—uterine cancer	8.87e-07	4.09e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—STAR—uterine cancer	8.87e-07	4.09e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	8.82e-07	4.06e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—MTHFR—uterine cancer	8.81e-07	4.06e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—EP300—uterine cancer	8.72e-07	4.01e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—EP300—uterine cancer	8.63e-07	3.97e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—DCN—uterine cancer	8.62e-07	3.97e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CYP11A1—uterine cancer	8.62e-07	3.97e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CYP19A1—uterine cancer	8.6e-07	3.96e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—STK11—uterine cancer	8.6e-07	3.96e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	8.53e-07	3.93e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CXCL8—uterine cancer	8.5e-07	3.91e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—HRAS—uterine cancer	8.43e-07	3.88e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—KRAS—uterine cancer	8.38e-07	3.86e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CDKN1B—uterine cancer	8.3e-07	3.82e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	8.21e-07	3.78e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—VEGFA—uterine cancer	8.17e-07	3.76e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—AKR1C3—uterine cancer	8.14e-07	3.75e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CYP11A1—uterine cancer	8.12e-07	3.74e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—AKT1—uterine cancer	8.1e-07	3.73e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—NRAS—uterine cancer	8.07e-07	3.72e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—PIK3CA—uterine cancer	7.91e-07	3.64e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CTNNB1—uterine cancer	7.84e-07	3.61e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—ERBB2—uterine cancer	7.8e-07	3.59e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—PIK3CA—uterine cancer	7.7e-07	3.55e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—AKR1C3—uterine cancer	7.67e-07	3.53e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—PTEN—uterine cancer	7.64e-07	3.52e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—PIK3CA—uterine cancer	7.63e-07	3.51e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—AKT1—uterine cancer	7.45e-07	3.43e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PTEN—uterine cancer	7.42e-07	3.41e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—EP300—uterine cancer	7.29e-07	3.36e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CDKN1B—uterine cancer	7.22e-07	3.33e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—HRAS—uterine cancer	7.12e-07	3.28e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PTEN—uterine cancer	7.11e-07	3.27e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—PIK3CA—uterine cancer	7.1e-07	3.27e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—EP300—uterine cancer	7.07e-07	3.26e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—POLD1—uterine cancer	6.96e-07	3.21e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—KRAS—uterine cancer	6.95e-07	3.2e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—VEGFA—uterine cancer	6.9e-07	3.18e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CTNNB1—uterine cancer	6.82e-07	3.14e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—NRAS—uterine cancer	6.82e-07	3.14e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—EP300—uterine cancer	6.78e-07	3.12e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PTEN—uterine cancer	6.65e-07	3.06e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—AKR1C1—uterine cancer	6.51e-07	3e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—AKT1—uterine cancer	6.46e-07	2.98e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—MTHFR—uterine cancer	6.46e-07	2.97e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PIK3CA—uterine cancer	6.45e-07	2.97e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—PIK3CA—uterine cancer	6.38e-07	2.94e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—EP300—uterine cancer	6.34e-07	2.92e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—STK11—uterine cancer	6.34e-07	2.92e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CYP19A1—uterine cancer	6.34e-07	2.92e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—AKT1—uterine cancer	6.29e-07	2.9e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—AKT1—uterine cancer	6.24e-07	2.87e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—TP53—uterine cancer	6.17e-07	2.84e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—STK11—uterine cancer	5.97e-07	2.75e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CYP19A1—uterine cancer	5.97e-07	2.75e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—NRAS—uterine cancer	5.93e-07	2.73e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—HRAS—uterine cancer	5.9e-07	2.72e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—KRAS—uterine cancer	5.87e-07	2.7e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—RRM2—uterine cancer	5.8e-07	2.67e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—AKT1—uterine cancer	5.8e-07	2.67e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—DCN—uterine cancer	5.63e-07	2.59e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PTEN—uterine cancer	5.57e-07	2.56e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—PIK3CA—uterine cancer	5.39e-07	2.48e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PTEN—uterine cancer	5.39e-07	2.48e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—EP300—uterine cancer	5.31e-07	2.45e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CYP11A1—uterine cancer	5.31e-07	2.44e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—AKT1—uterine cancer	5.27e-07	2.43e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PIK3CA—uterine cancer	5.23e-07	2.41e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—TP53—uterine cancer	5.22e-07	2.4e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—AKT1—uterine cancer	5.21e-07	2.4e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—EP300—uterine cancer	5.14e-07	2.37e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—KRAS—uterine cancer	5.11e-07	2.35e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PIK3CA—uterine cancer	5.02e-07	2.31e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—AKR1C3—uterine cancer	5.01e-07	2.31e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—HRAS—uterine cancer	4.99e-07	2.3e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PTEN—uterine cancer	4.9e-07	2.26e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—MTHFR—uterine cancer	4.76e-07	2.19e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PIK3CA—uterine cancer	4.69e-07	2.16e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—EP300—uterine cancer	4.67e-07	2.15e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—MTHFR—uterine cancer	4.49e-07	2.07e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—AKT1—uterine cancer	4.41e-07	2.03e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—HRAS—uterine cancer	4.34e-07	2e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—AKT1—uterine cancer	4.27e-07	1.97e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—AKT1—uterine cancer	4.1e-07	1.89e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PIK3CA—uterine cancer	3.93e-07	1.81e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—STK11—uterine cancer	3.91e-07	1.8e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CYP19A1—uterine cancer	3.91e-07	1.8e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—AKT1—uterine cancer	3.83e-07	1.76e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PIK3CA—uterine cancer	3.8e-07	1.75e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PTEN—uterine cancer	3.59e-07	1.65e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PIK3CA—uterine cancer	3.46e-07	1.59e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—EP300—uterine cancer	3.43e-07	1.58e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—AKT1—uterine cancer	3.21e-07	1.48e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—AKT1—uterine cancer	3.11e-07	1.43e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—MTHFR—uterine cancer	2.94e-07	1.35e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—AKT1—uterine cancer	2.82e-07	1.3e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PTEN—uterine cancer	2.65e-07	1.22e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PIK3CA—uterine cancer	2.53e-07	1.17e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—EP300—uterine cancer	2.53e-07	1.16e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PTEN—uterine cancer	2.5e-07	1.15e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—EP300—uterine cancer	2.38e-07	1.1e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—AKT1—uterine cancer	2.07e-07	9.53e-06	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PIK3CA—uterine cancer	1.87e-07	8.61e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PIK3CA—uterine cancer	1.76e-07	8.11e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PTEN—uterine cancer	1.63e-07	7.52e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—EP300—uterine cancer	1.56e-07	7.17e-06	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—AKT1—uterine cancer	1.53e-07	7.03e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—AKT1—uterine cancer	1.44e-07	6.63e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.15e-07	5.3e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—AKT1—uterine cancer	9.41e-08	4.33e-06	CbGpPWpGaD
